NYSE:GRDN Guardian Pharmacy Services (GRDN) Stock Price, News & Analysis $21.41 -0.43 (-1.97%) (As of 12/20/2024 04:33 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends About Guardian Pharmacy Services Stock (NYSE:GRDN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GRDN alerts:Sign Up Key Stats Today's Range$21.20▼$22.1450-Day Range$17.08▼$25.1852-Week Range$14.16▼$25.74Volume1.86 million shsAverage Volume191,270 shsMarket Capitalization$1.36 billionP/E RatioN/ADividend YieldN/APrice Target$22.00Consensus RatingBuy Company OverviewGuardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.Read More… Guardian Pharmacy Services Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks8th Percentile Overall ScoreGRDN MarketRank™: Guardian Pharmacy Services scored higher than 8% of companies evaluated by MarketBeat, and ranked 913th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingGuardian Pharmacy Services has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGuardian Pharmacy Services has only been the subject of 3 research reports in the past 90 days.Read more about Guardian Pharmacy Services' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings Growth-3.45% Earnings GrowthEarnings for Guardian Pharmacy Services are expected to decrease by -3.45% in the coming year, from $0.87 to $0.84 per share. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GRDN. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGuardian Pharmacy Services does not currently pay a dividend.Dividend GrowthGuardian Pharmacy Services does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for GRDN. News and Social Media2.3 / 5News Sentiment1.10 News SentimentGuardian Pharmacy Services has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Guardian Pharmacy Services this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for GRDN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Guardian Pharmacy Services to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Guardian Pharmacy Services insiders have bought more of their company's stock than they have sold. Specifically, they have bought $648,536.00 in company stock and sold $0.00 in company stock.Read more about Guardian Pharmacy Services' insider trading history. Receive GRDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardian Pharmacy Services and its competitors with MarketBeat's FREE daily newsletter. Email Address GRDN Stock News HeadlinesComparing HealthWarehouse.com (OTCMKTS:HEWA) & Guardian Pharmacy Services (NYSE:GRDN)December 19 at 1:11 AM | americanbankingnews.comGuardian Pharmacy Services Inc. Cl ANovember 27, 2024 | wsj.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… December 22, 2024 | Crypto 101 Media (Ad)Guardian Pharmacy price target raised to $24 from $22 at TruistNovember 15, 2024 | markets.businessinsider.comGuardian Pharmacy reports Q3 adjusted EBITDA $23.0M, up 20% y/yNovember 13, 2024 | markets.businessinsider.comGuardian Pharmacy sees FY24 revenue $1.205B-$1.215B, consensus $1.19BNovember 13, 2024 | markets.businessinsider.comGuardian Pharmacy Services, Inc. Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | businesswire.comGuardian Pharmacy Services, Inc. to Report Third Quarter 2024 Financial Results and Host Conference CallOctober 30, 2024 | finance.yahoo.comSee More Headlines GRDN Stock Analysis - Frequently Asked Questions How have GRDN shares performed this year? Guardian Pharmacy Services' stock was trading at $17.75 at the start of the year. Since then, GRDN stock has increased by 20.6% and is now trading at $21.41. View the best growth stocks for 2024 here. How were Guardian Pharmacy Services' earnings last quarter? Guardian Pharmacy Services, Inc. (NYSE:GRDN) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($2.00) earnings per share for the quarter, missing the consensus estimate of $0.19 by $2.19. The business had revenue of $314.39 million for the quarter, compared to analysts' expectations of $303.21 million. When did Guardian Pharmacy Services IPO? Guardian Pharmacy Services (GRDN) raised $102 million in an initial public offering (IPO) on Thursday, September 26th 2024. The company issued 6,800,000 shares at $14.00-$16.00 per share. Raymond James, Stifel and Truist Securities acted as the underwriters for the IPO. When did the company's quiet period expire? Guardian Pharmacy Services' quiet period expired on Tuesday, November 5th. Guardian Pharmacy Services had issued 8,000,000 shares in its initial public offering on September 26th. The total size of the offering was $112,000,000 based on an initial share price of $14.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company. Who are Guardian Pharmacy Services' major shareholders? Guardian Pharmacy Services' top institutional shareholders include Wellington Management Group LLP (0.81%), Franklin Resources Inc. (0.79%), Allspring Global Investments Holdings LLC (0.52%) and Maven Securities LTD (0.29%). Insiders that own company stock include Thomas J Salentine Jr and Steven D Cosler. View institutional ownership trends. How do I buy shares of Guardian Pharmacy Services? Shares of GRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Guardian Pharmacy Services own? Based on aggregate information from My MarketBeat watchlists, some other companies that Guardian Pharmacy Services investors own include UnitedHealth Group (UNH) and Meta Platforms (META). Company Calendar Last Earnings11/12/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Drug stores & proprietary stores Sub-IndustryN/A Current SymbolNYSE:GRDN Previous SymbolNYSE:GRDN CUSIPN/A CIK1802255 Webguardianpharmacy.com Phone(404) 810-0089FaxN/AEmployees3,200Year FoundedN/APrice Target and Rating Average Stock Price Target$22.00 High Stock Price Target$24.00 Low Stock Price Target$21.00 Potential Upside/Downside+2.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.17 billion Price / Sales1.16 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares63,294,000Free FloatN/AMarket Cap$1.36 billion OptionableN/A BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NYSE:GRDN) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guardian Pharmacy Services, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Guardian Pharmacy Services With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.